Japanese firms Veneno Technologies and ASKA Pharmaceutical have entered into a joint research agreement to conduct a drug discovery program to obtain functional disulfide-rich peptides (DRPs) for ion channels selected by the companies.
This work will be conducted using Veneno’s next-generation peptide discovery technology, PERISSTM, with the aim of developing new therapeutic drugs.
DRPs are a general term for peptides with multiple disulfide bonds in the molecule, usually consisting of 20 to 80 amino acids.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze